Cargando…
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work better for STK11 or KEAP1 mutated (SKmut) aNSCLC pa...
Autores principales: | Nie, Wei, Gan, Lu, Wang, Xin, Gu, Kai, Qian, Fang-Fei, Hu, Min-Juan, Zhang, Ding, Chen, Shi-Qing, Lu, Jun, Cao, Shu-Hui, Li, Jing-Wen, Wang, Yue, Zhang, Bo, Wang, Shu-Yuan, Li, Chang-Hui, Yang, Ping, Xu, Mi–Die, Zhang, Xue-Yan, Zhong, Hua, Han, Bao-Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833760/ https://www.ncbi.nlm.nih.gov/pubmed/33537171 http://dx.doi.org/10.1080/2162402X.2020.1865670 |
Ejemplares similares
-
The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration
por: Zhang, Chenyue
Publicado: (2021) -
A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
por: Nie, Wei, et al.
Publicado: (2020) -
XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
por: Li, Xuanzong, et al.
Publicado: (2021) -
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
por: Papillon-Cavanagh, Simon, et al.
Publicado: (2020) -
Characterization of the STK11 splicing variant as a normal splicing isomer in a patient with Peutz–Jeghers syndrome harboring genomic deletion of the STK11 gene
por: Masuda, Kenta, et al.
Publicado: (2016)